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Background: Ritonavir is a HIV protease inhibitor. In addition to its antiviral effect, Ritonavir directly inhibits the
insulin-regulated glucose transporter GLUT4 and blocks glucose entry into fat and muscle cells. However, the effect
of Ritonavir on cardiac GLUT4 inhibition during myocardial necrosis is not investigated. In the present study, we
evaluated the role of Ritonavir in isoproterenol-induced myocardial necrosis in vivo and compared the effect with
Phlorizin, a nonslective SGLTs inhibitor.
Methods: Isoproterenol (ISO) (150 mg/kg/day, i.p for 2 consecutive days) was administered to mice to cause
myocardial necrosis. Phlorizin (400 mg/kg/day i.p twice daily for 2 days) and Ritonavir (10 mg/kg/day i.p twice daily
for 2 days) were administered in two different groups of mice before isoproterenol administration.
Results and discussion: Isoproterenol (ISO) (150 mg/kg/day, i.p for 2 consecutive days) administration caused
significant (p < 0.05) increase in heart/body weight ratio, and myocardial necrosis as evident by significant (p < 0.05)
increase in serum markers i.e. SGOT and CK; and cardiac histopathological changes. Significant (p < 0.05) reduction
in myocardial SOD and catalase activities, and GSH level along with a significant (p < 0.05) rise in myocardial TBARS
and nitric oxide levels were observed after ISO administration. However, administration of phlorizin, a SGLT1
inhibitor has been found to exhibit partial protection in ISO induced myocardial necrosis, as observed by significant
decrease in heart/body weight ratio and myocardial nitric oxide level; significant increase in myocardial SOD and
catalase activities along with no histopathological alterations. On the other hand, administration of ritonavir, a
nonspecific GLUT inhibitor has been found to exhibit complete protection as observed by normalisation of heart/
body weight ratio, serum markers, antioxidant enzymes activities and histopathological alterations. In vitro study
with heart homogenate confirmed no antioxidant effect of ritonavir and phlorizin in the absence and presence of
isoproterenol.
Conclusions: Our study concluded that ritonavir, a nonspecific GLUT inhibitors showed complete protection in
catecholamine induced myocardial necrosis.
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Myocardial infarction (MI) is one of the main causes of
death from cardiovascular disease. MI is defined as an
acute condition of necrosis of the myocardium that oc-
curs as a result of imbalance between coronary blood
supply and myocardial demand [1]. The heart is cap-
able of utilizing a variety of metabolic substrates and is
able to switch rapidly depending on pathological and
physiological conditions. Although, glucose and fatty
acid are mainly used as fuel for energy in the heart,
fatty acid remains a major source of energy [2]. How-
ever, in an ischemic heart due to less availability of
oxygen, glucose becomes the major source of energy,
as glycolysis switches from aerobic to anaerobic condi-
tions. Such metabolic perturbation is seen in various
cardiac diseases which result in shifting of metabolic
utilization of substrates toward glucose from fatty
acids [3].
In mammalian heart, glucose transport is believed to
be mediated mainly by two members of the GLUT fam-
ily, GLUT1 and GLUT4. Increased activity of GLUTs in
diseased heart has been reported earlier [2]. SGLT is an-
other group of glucose transporter which is mainly in-
volved in absorption of glucose from renal and intestinal
tissue. It was reported that SGLT1 is 10 times more
expressed in human cardiomyocytes than kidney tissue
[4] and their increased cardiac expression in different
heart diseases in mice as well as in human has been
reported recently [5,6]. However the role of SGLT1 in
heart is still not clear. Thus further investigating the role
of GLUTs and SGLT1 inhibitors during cardiac injury
and their comparison is of great importance.
In the present study, we inhibited SGLTs and GLUTs
transporters in heart by using pharmacological inhibi-
tors, phlorizin (nonselective SGLT blocker) and ritonavir
(nonselective GLUTs blocker) respectively, and evaluated
the relative importance of these transporters during
myocardial necrosis induced by isoproterenol.Materials and methods
Animals
Male Swiss albino mice (20-25 gm) were provided by
National Institute of Nutrition (NIN), Hyderabad. The
animals were housed in BIOSAFE, an animal quarantine
facility of Indian Institute of Chemical Technology
(IICT) Hyderabad. The animal house was maintained at
temperature 22 ± 2°C, relative humidity 50 ± 15% and
12 hour dark/light cycle was maintained throughout the
study. Mice had free access to food (pellet diet supplied
from NIN, Hyderabad) and water ad libitum. All animal
experiments were undertaken with the approval of Insti-
tutional Animal Ethics Committee of Indian Institute of
Chemical Technology, Hyderabad, India.Experimental protocols
Weight matched male swiss albino mice were randomly
divided into four groups with each group having eight
animals. Six and two animals from each group were kept
for biochemical and histopathological evaluation, re-
spectively. The doses used in this study were selected on
the basis of reports of previous studies [7,8].
 Control group (IP injection of physiological saline
and vehicle 0.2 ml/day).
 ISO group (SC injection of ISO 150 mg/kg/day for 2
consecutive days).
 ISO+Phz group (IP injection of phlorizin
400 mg/kg/day 10 min. prior to ISO dose for
2 days).
 ISO+RTV group (IP injection of ritonavir
10 mg/kg/day 10 min. prior to ISO dose for 2 days).
ISO is dissolved in PBS while phlorizin and ritonavir
were dissolved in vehicle (75% PBS +15% DMSO + 10%
absolute alcohol). Control group received phosphate buf-
fer saline (PBS) and vehicle at the time of ISO and
‘phlorizin and ritonavir’ administration, respectively. ISO
group received vehicle at the time of phlorizin and rito-
navir administration.Sample collection and biochemical assay
The animals in all groups were sacrificed 48 hrs after
first dose of isoproterenol injection. Cardiac tissues were
collected and stored at - 80°C for further biochemical
evaluation. At the time of sacrifice, blood was collected
by cardiac puncture, serum was separated by centrifuga-
tion at 4000 rpm (4°C) for 15 minutes and serum
markers (SGOT and CK) were analysed by auto blood
analyser (Bayer diagnostic). SGOT and CK were ex-
pressed in IU/L.Assessment of biochemical parameters
Each heart was homogenized with 20 times volume of
heart weight in ice cold 0.05 M potassium phosphate
buffer and treated separately as described below for the
measurement of different biochemical parameters [9].
20% homogenate was diluted with 10% trichloro acetic
acid (TCA) in 1:1 ratio then centrifuged at 5000 rpm for
10 min. Supernatant was separated for GSH estimation
as described [10]. Rest 80% homogenate was centrifuged
at 15,000 rpm for 60 min. Supernatant was separated for
estimation of nitric oxide (Nitric oxide assay kit, Assay
Design), superoxide dismutase (SOD) (SOD kit, Fluka)
and catalase [11]. Pallets from both homogenates were
taken and resuspended in 1 ml of 10% TCA solution for
TBARS estimation as earlier described [12].
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All cardiac samples after euthenisation were fixed in 10%
neutral buffer formalin. Paraffin embedded 5 μm thick
sections were obtained and stained with Hematoxylin
and Eosin (H&E stain). Prepared sections were examined
under light microscope to assess gross myocyte injury
and the effects of interventions.
In vitro antioxidant assay
Adult male swiss albino mice were euthanized. Heart
was excised, washed with 0.9% NaCl solution and
homogenised with 20-times volume of heart weight in
0.05 M ice-cold phosphate buffer [pH 7.4] [13]. Heart
homogenate (0.25 ml) was mixed with 0.1 ml of 0.05 M
phosphate buffer (pH 7.4), 0.05 ml of 0.1 mM ascorbic
acid, 0.05 ml of 4 mM FeCl2 solution and 0.05 ml of
the test sample. The mixture was incubated at 37°C for
1 hour and estimated for thiobarbituric acid reactive
substances (TBARS). TBARS levels in heart homogenate
were measured after treatment with phlorizin (450 μM)
and ritonavir (15 μM) in presence and absence of iso-
proterenol (1.0 M). Data were expressed as nanomoles/
ml homogenate using extinction co-efficient of MDA
(1.56 × 10-5 M-1 cm-1).
Statistical analysis
All values were expressed as mean ± SEM. Data were
statistically analyzed using one way ANOVA for multiple
group comparison, followed by student unpaired ‘t’
test for group wise comparison. Significance was set at
P ≤ 0.05. Data were computed for statistical analysis by
using Graph Pad Prism Software.
Results
Heart weight / Body weight Ratio
A significant (p ≤ 0.001) increase in heart weight / body
weight ratio was observed in ISO group in comparison
to control. However, significant (p ≤ 0.05) decrease in
heart weight / body weight ratio was observed both in
ISO + Phz and ISO + RTV groups in comparison to ISO
group (Table 1).
Serum parameters
SGOT and CK levels were significantly increased
(p < 0.05) in ISO group in comparison to control group.
Significant (p < 0.05) increase in SGOT level but no
change in CK level was observed in ISO + Phz group.
However, significant (p < 0.05) decrease in both SGOTTable 1 Heart weight / body weight ratio in different experim
Groups Control
Heart weight / Body weight × 10-3 5.33 ± 0.11
All the values were expressed Mean ± SEM, (N = 8) ***p < 0.001 vs. control group; †pand CK levels was observed in ISO + RTV group in com-
parison to ISO group (Table 2).
Myocardial TBARS and Nitric oxide
Myocardial TBARS and nitric oxide levels were signifi-
cantly increased (p < 0.01) in ISO group in comparison
to control. There was significant (p < 0.05) decrease in
myocardial nitric oxide level but no change in myocar-
dial TBARS level in ISO + Phz group in comparison to
ISO group. However, there was significant (p < 0.05) de-
crease in both myocardial TBARS and nitric oxide level
in ISO + RTV group in comparison to ISO (Table 3).
Myocardial GSH, catalase and superoxide
dismutase (SOD)
Myocardial GSH, catalase and SOD were significantly
decreased (p < 0.05) in ISO group in comparison to con-
trol group. There was significant (p < 0.01) increase in
both myocardial catalase and SOD level but no signifi-
cant change in myocardial GSH level in ISO + Phz group
in comparison to ISO. However, significant (p < 0.05) in-
crease in all three parameters was observed in ISO +
RTV group in comparison to ISO (Table 3).
Histopathology
H&E sections from ISO group showed the features of se-
vere inflammation along with presence of inflammatory
cells, vacuolization of myocytes and focal areas of
myocytolysis. However, H&E sections from ISO + phz
and ISO + RTV groups showed no signs of any injury
(Figure 1).
In vitro antioxidant effect
In vitro antioxidant assay was performed with heart
homogenate in presence and absence of isoproterenol.
In absence of isoproterenol, no significant change in
TBARS level was observed after both phlorizin (Phz
group) and ritonavir (RTV group) treatment in compari-
son to control. Significant (p < 0.05) increase in TBARS
level was observed after addition of isoproterenol (ISO
group). However, no significant change in TBARS level
was observed in ISO group after phlorizin (ISO + Phz
group) and ritonavir (ISO + RTV group) treatment in
comparison to ISO group (Table 4).
Discussion
Excessive release of catecholamine is associated with
typical myocardial pathology under stressful conditions.
Catecholamine and its metabolites play an importantental groups
ISO ISO + Phz ISO + RTV
6.38 ± 0.20*** 5.89 ± 0.13† 5.57 ± 0.09†††
< 0.05, †††p < 0.001 vs. ISO group.
Table 2 Serum SGOT and CK activities in different
experimental groups
Group SGOT (IU/L) CK (IU/L)
Control 62.12 ± 5.03 287.66 ± 33.08
ISO 79.20 ± 6.52* 474.00 ± 63.28**
ISO + Phz 104.66 ± 4.78†† 495.01 ± 130.57
ISO + RTV 65.80 ± 4.33† 301.80 +5.51†
All the values were expressed Mean ± SEM, (N = 6) *p < 0.05, **p <0.01, vs
Control group; †p < 0.05, ††p < 0.01, vs ISO group.
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stress in heart. Although cardiotoxicity occurs primarily
via adrenoceptor activation [14], increasing evidence
suggests that it may also occur through oxidative mecha-
nisms [15-17]. Dhalla et al. (1996) have reported that ex-
cess catecholamine affects calcium transport mechanism
primarily via free radical mediated oxidative damage
[17]. Thus β1-adrenoceptor antagonist and antioxidants
may be indicated the best therapy for stress induced
heart disease. Along with oxidative stress, increased car-
diac glucose uptake was observed after catecholamine
administration [18]. Glucose is also one of the major
sources of energy in ischemic and stressed heart [3].
However, the effect of glucose transporter inhibition
during catecholamine-induced cardiac injury was not
observed previously. We administered phlorizin (SGLTs
inhibitor) and ritonavir (GLUTs inhibitor) in isopro-
terenol-induced injured heart and observed their role
in heart.
In the present study, we have observed a significant in-
crease in heart weight and body weight ratio in ISO-
induced mice. This increase in heart weight appears to
be a hypertrophic response. Isoproterenol induced car-
diac hypertrophy was also reported earlier [7]. The ob-
served increase in the heart weight in ISO induced mice
might be due to increase in protein synthesis and inva-
sion of inflammatory cells in necrotic tissue [19]. In-
creased glucose uptake in heart along with increased
oxidative stress in ISO administration might be respon-
sible for cardiac hypertrophy. Association of cardiac
hypertrophy and increased glucose uptake in heart was
reported earlier [5,20]. Thus, both phlorizin and ritona-
vir (SGLT1 and GLUT inhibitor respectively) attenuatedTable 3 Myocardial TBARS, Nitric oxide, GSH, Catalase and SO
Groups TBARS (nmoles / gm heart
wt.)
Nitric oxide (μmole / mg
protein)
G
Control 27.99 ± 4.25 0.018 ± 0.001
ISO 47.81 ± 5.70** 0.023 ± 0.001**
ISO +
Phz
36.40 ± 6.58 0.019 ± 0.001†
ISO +
RTV
28.93 ± 4.03† 0.018 ± 0.001†
All the values were expressed Mean ± SEM, (N = 6) *p < 0.05, **p <0.01, ***p <0.001ISO induced cardiac hypertrophy might be via inhibiting
glucose uptake in heart.
During myocardial injury cardiac membranes becomes
leaky and results in higher serum level of creatine kinase
(CK) and SGOT enzymes. These enzymes enter into the
blood stream and thus increasing their concentration in
the serum, and serve as the diagnostic markers of myo-
cardial tissue damage [21-23]. Isoproterenol is well
known cardiotoxic agent due to its ability to damage cell
membrane. A significant elevated level of serum SGOT
and CK after isoproterenol treatment was reported in
mice earlier [7]. In the present study, we have observed
elevated levels of serum SGOT and CK after ISO admin-
istration. Similar to ISO group, there were elevated ac-
tivities of CK and SGOT in case of phlorizin. Unlike
phlorizin, ritonavir showed complete cardioprotection
by abrogating ISO effects.
Lipid peroxidation and endogenous antioxidants were
also measured to confirm the myocardial oxidative stress
after administration of isoproterenol. Isoproterenol pro-
duce quinones which react with oxygen to generate
superoxide anions [O2 · -] and H2O2, which have dam-
aging effects in cells [24]. ISO induced oxidative stress
can be characterized by reduction of myocardial SOD,
catalase and GSH along with a rise in myoacardial
TBARS level [7,22,25]. It was previously reported that
ISO could activates nitric oxide synthase (NOS) and in-
crease the formation of reactive nitrogen species (RNS)
during myocardial infarction [26]. Increased myocardial
lipid peroxidation after isoproterenol appears to be the
initial event of oxidative damage. In the present study,
we have observed significant reduction of myocardial
SOD and catalase activity, myocardial GSH and ele-
vation of myocardial TBARS and nitric oxide, which
confirms ISO-induced myocardial oxidative stress. Ad-
ministration of phlorizin in ISO-treated mice only im-
proved myocardial SOD, catalase and nitric oxide levels
but no change in myocardial TABRS and GSH. Hence,
phlorizin showed partial protection against ISO-induced
myocardial oxidative stress. However, ritonavir normal-
ized all oxidative stress parameters and thus showed
complete protection against myocardial oxidative stress
potentiated by isoproterenol. Although, the antioxidantD in different experimental groups
SH (mg / gm heart
wt.)
Catalase (units / mg
protein)
SOD (units / mg
protein)
4.22 ± 0.45 7.82 ± 0.15 313.89 ± 13.69
3.05 ± 0.09* 5.60 ± 0.14*** 245.33 ± 7.45**
3.37 ± 0.59 7.98 ± 0.52†† 320.42 ± 12.44††
4.75 ± 0.72† 7.95 ± 0.49†† 372.41 ± 18.80†††
vs Control group; † p < 0.05, † † p < 0.01, † † † p < 0.001 vs ISO group.
Control ISO
ISO + Phz ISO + RTV
A B
C D
Figure 1 Histopathological changes in mice heart (n = 2). A. Control group: myocardial structure is intact with cardiomyocytes lined up in
order (HE, 200X). B ISO group: photomicrograph showing formation of intracytoplasmic vacuolization, myocytolysis with diffused lymphocytes
and monocytes infiltration (HE, 200X). C. ISO + Phz group: Photomicrograph of cardiac muscle showing normal architecture (HE, 200X). D. ISO +
RTV group: Photomicrograph of cardiac muscle showing normal architecture (HE, 200X).
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earlier [27], no antioxidant property is reported so far by
ritonavir.
To further confirm whether phlorizin and ritonavir
have any antioxidant property, we did in-vitro antioxi-
dant assay with heart homogenate. Our study showed no
significant change in TBARS level, a marker of lipid per-
oxidation, after addition of phlorizin and ritonavir in
heart homogenate in absence or presence of iso-
proterenol. This indicates that both phlorizin and ritona-
vir had no additional antioxidant effect in presence of
isoproterenol. Thus the cardioprotective effect of phlo-
rizin and ritonavir might be due to the inhibition of glu-
cose uptake in heart.able 4 TBARS levels in heart homogenate after
reatment with different pharmacological agents in
-vitro
roups TBARS (nmoles /mL homogenate)
Control 8.61 ± 0.15
ISO 12.40 ± 0.15*
Phz 8.03 ± 0.12
RTV 8.23 ± 0.90
O + Phz 12.68 ± 0.58*
O + RTV 13.23 ± 0.50*






AISO-induced myocardial necrosis is also confirmed by
histopathological findings. ISO-treated heart showed the
features of severe inflammation, the presence of inflam-
matory cells between the fibers, vacuolation of myocytes
and few focal areas of myocytolysis. These all changes
were previously reported in various ISO-induced myo-
cardial necrosis models [23,25]. However, administration
of either phlorizin or ritonavir showed no sign of cardiac
necrosis in histopathology.
Catecholamine or isoproterenol generally increases
heart rate and glucose uptake in heart. The reason of
myocardial injury by isoproterenol might be through cat-
echolamine induced free radical generation. It is possible
that increased glucose uptake in heart might be respon-
sible for more free radical generation and oxidative
stress. Our present study showed that inhibition of car-
diac glucose uptake through GLUT and SGLT1 blockers
were beneficial for ISO-induced necrotic heart. We
found partial protection by phlorizin, a SGLT1 inhibitor,
in ISO-induced myocardial necrosis in mice. This pro-
tection might be possible through inhibition of cardiac
glucose uptake through SGLT1 glucose transporter.
Most important finding in our study is that ritonavir
(GLUTs inhibitor) provides complete protection in ISO
induced myocardial necrosis. It attenuated heart/body
weight ratio, serum markers and oxidative stress. Hence
ritonavir proved to be a better cardioprotective agent
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myocardial necrosis.
Thus our study concludes that non-specific GLUT in-
hibitor, ritonavir showed complete protection during
ISO-induced myocardial necrosis. However, further
studies should be carried out to find out whether ritona-
vir possess cardioprotection through additional effect
unrelated to glucose transporter inhibition.
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